India becomes first country to approve STIMULAN Rapid Cure with antifungals
Surgical site infections and antimicrobial resistance remain major challenges globally
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated